Veritas In Silico

November 3rd, 2026

Company Name: Veritas In Silico Inc.
Representative: Shingo NAKAMURA,
Representative Director and CEO
Listed on: TSE Growth
Stock Ticker Code: 130A
Contact : Tsuneo GODA,
Executive Officer, General Manager,
Corporate Planning Division
Email: ir@veritasinsilico.com

Conferment of the Purple Ribbon Medal of Honor upon Kazuhiko NAKATANI, Senior Research Fellow of Veritas In Silico

Veritas In Silico Inc. (Headquarters: Shinagawa-ku, Tokyo; Representative Director and CEO: Shingo NAKAMURA, hereinafter referred to as "the Company") hereby announces that Kazuhiko NAKATANI, Senior Research Fellow of the Company, Professor Emeritus of Osaka University and Visiting Professor at the Institute of Scientific and Industrial Research, Osaka University, has been awarded the Purple Ribbon Medal of Honor.

The Purple Ribbon Medal of Honor is a Japanese national honor bestowed upon individuals who have achieved distinction in scientific and technological innovation, academia, sports, or the arts and culture.

For many years, NAKATANI has pursued research into the interactions between nucleic acids and small-molecule compounds. He has held a number of leadership positions at Osaka University, including Professor and Director of the Institute of Scientific and Industrial Research, as well as Executive Vice President. In particular, his pioneering work on small-molecule compounds that target RNA has helped advance this field of research.

Following his retirement from the University, Professor NAKATANI remained committed to continuing his research at the forefront of the field. In April 2026, he joined Veritas In Silico as a Senior Research Fellow.

The Company believes that his continued pursuit of new challenges in an industrial research setting, drawing on his extensive academic experience, offers an inspiring example of how researchers can build careers that carry their university-based expertise into new research environments.

● Comments from Kazuhiko NAKATANI, Senior Research Fellow of Veritas In Silico

I am deeply honored to receive the Purple Ribbon Medal of Honor, a distinction of the highest prestige. I extend my heartfelt gratitude to all those who have worked alongside me

throughout my research career, as well as to everyone who has supported and encouraged my endeavors.

RNA-targeted small-molecule drug discovery, to which I have devoted my efforts, is a field attracting growing interest from academia and industry worldwide. Following my retirement from Osaka University, I wished to remain at the forefront of research, and since April 2026, I have had the privilege of continuing my work as a researcher at Veritas In Silico Inc.

I sincerely hope that this honor will contribute to the further advancement of RNA-targeted small-molecule drug discovery research in Japan and at Veritas In Silico.

● Comments from Shingo NAKAMURA, Representative Director and CEO of Veritas In Silico

Please accept my heartfelt congratulations on your receipt of the Purple Ribbon Medal of Honor. This distinguished recognition is a fitting tribute to your remarkable achievements.

For twenty years, we have worked together toward the realization of small-molecule medicines targeting mRNA. The research we pursued alongside Professor Gota KAWAI — formerly Professor in the Department of Bioscience, Graduate School of Advanced Engineering, Chiba Institute of Technology, and now Representative Director of Resorna Inc. and Scientific Advisor of the Company — has been a profoundly meaningful part of my life. Together, we established research forums and organizations and worked to communicate the promise of RNA-targeted drug discovery to society. I am deeply moved by this honor, which recognizes not only your outstanding accomplishments but also, in a sense, the significance of the research we have advanced together.

I am sincerely grateful that, even after your retirement from the University, you have remained devoted to research and joined our work at the Company. To me, you are a valued colleague and trusted partner. Together, we will continue our efforts to translate the research we have pursued into medicines.

Once again, please accept my warmest congratulations on this well-deserved honor.

The Company is going to draw inspiration from this distinguished honor as it pursues research and development aimed at realizing mRNA-targeted small-molecule drug discovery within the broader field of RNA-targeted therapeutics, with the goal of creating innovative medicines that address unmet medical needs.

END

For Further Information, Contact:

● Veritas In Silico Website Inquiry Form : https://www.veritasinsilico.com/en/contact/